These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19619305)

  • 1. Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12.
    Dunfee RL; Thomas ER; Gabuzda D
    Retrovirology; 2009 Jul; 6():69. PubMed ID: 19619305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.
    Peters PJ; Duenas-Decamp MJ; Sullivan WM; Brown R; Ankghuambom C; Luzuriaga K; Robinson J; Burton DR; Bell J; Simmonds P; Ball J; Clapham PR
    Retrovirology; 2008 Jan; 5():5. PubMed ID: 18205925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia.
    Dunfee RL; Thomas ER; Wang J; Kunstman K; Wolinsky SM; Gabuzda D
    Virology; 2007 Oct; 367(1):222-34. PubMed ID: 17599380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic Correlates of HIV-1 Macrophage Tropism.
    Arrildt KT; LaBranche CC; Joseph SB; Dukhovlinova EN; Graham WD; Ping LH; Schnell G; Sturdevant CB; Kincer LP; Mallewa M; Heyderman RS; Rie AV; Cohen MS; Spudich S; Price RW; Montefiori DC; Swanstrom R
    J Virol; 2015 Nov; 89(22):11294-311. PubMed ID: 26339058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism.
    O'Connell O; Repik A; Reeves JD; Gonzalez-Perez MP; Quitadamo B; Anton ED; Duenas-Decamp M; Peters P; Lin R; Zolla-Pazner S; Corti D; Wallace A; Wang S; Kong XP; Lu S; Clapham PR
    J Virol; 2013 Jan; 87(1):187-98. PubMed ID: 23055568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
    Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of the 375W mutation for HIV-1 tropism and vaccine development.
    Verdejo-Torres O; Vargas-Pavia T; Fatima S; Clapham PR; Duenas-Decamp MJ
    J Virol; 2024 Jan; 98(1):e0152223. PubMed ID: 38169306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission.
    Yen PJ; Herschhorn A; Haim H; Salas I; Gu C; Sodroski J; Gabuzda D
    J Virol; 2014 May; 88(9):5014-28. PubMed ID: 24554659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue.
    Gonzalez-Perez MP; O'Connell O; Lin R; Sullivan WM; Bell J; Simmonds P; Clapham PR
    Retrovirology; 2012 Mar; 9():20. PubMed ID: 22420378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
    Utachee P; Nakamura S; Isarangkura-Na-Ayuthaya P; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Virol; 2010 May; 84(9):4311-20. PubMed ID: 20164234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
    Wu L; Zhou T; Yang ZY; Svehla K; O'Dell S; Louder MK; Xu L; Mascola JR; Burton DR; Hoxie JA; Doms RW; Kwong PD; Nabel GJ
    J Virol; 2009 May; 83(10):5077-86. PubMed ID: 19264769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.
    Musich T; Peters PJ; Duenas-Decamp MJ; Gonzalez-Perez MP; Robinson J; Zolla-Pazner S; Ball JK; Luzuriaga K; Clapham PR
    J Virol; 2011 Mar; 85(5):2397-405. PubMed ID: 21159865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
    Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
    Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.